Clinical trials: COX-2 Inhibitor
Nasopharyngeal Carcinoma
The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
The purpose of this study is to determine whether celecoxib is effective in the treatment of nasopharyngeal carcinoma by concurrent chemoradiation with weekly nedaplatin.
- Trial name
- NCT02537925
- Testing
- Celecoxib, Nedaplatin, Concurrent Radiotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changjie Huang
Contraception
On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility
This is an exploratory prospective study investigating if addition of a COX-2 inhibitor can increase efficacy of ulipristal in disrupting ovulation at peak fertility.
- Trial name
- NCT03354117
- Testing
- Ulipristal Acetate 30 MG Oral Tablet
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Stanford University
Biliary Atresia, Kasai Portoenterostomy Status
Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia
In this clinical study, meloxicam will be used to the patients who are older than 2 years and underwent Kasai portoenterostomy to treat their biliary atresia before.
- Trial name
- NCT02298218
- Testing
- Meloxicam
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Pancreatitis, Acute
COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- NCT02964403
- Testing
- Cox-2, Indomethacin
- Volunteers
- 2,700 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
SERRAC is a prospective, multicentre, randomized phase II trial. 138 LARC (T3-4/N+M0, distance from anal verge ≤10cm) patients will be treated with neoadjuvant therapy and assigned to Group A and Group B (1:1).
- Trial name
- NCT07150949
- Testing
- Long-course radiotherapy, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Fudan University
HIV
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients
Chronic immune activation is a central feature of HIV-infection, and the degree of activated T-cells is a better predictor of disease progression and mortality than plasma viral load.
- Trial name
- OUSCOX2 (NCT01269515)
- Testing
- Etoricoxib
- Where
- 2 sites in Norway
- Volunteers
- 60 people
- Sponsor
- Dag Kvale
Prostate Cancer
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00073970
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lung Cancer
Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00653250
- Testing
- celecoxib, biopsy, therapeutic conventional surgery
- Volunteers
- 22 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Cancer
Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2
This is a phase I study of second primary tumor prevention in early stage (stage I/II) patients diagnosed with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT00400374
- Testing
- Erlotinib, Celecoxib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Adverse Anesthesia Outcome
Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor
Acute pain is the result of activating nociceptive pathways in both the peripheral and central nervous system. The origin of most acute pain from surgical stimulation is the mechanical trauma of the local tissue and the…
- Trial name
- NCT02884986
- Testing
- Etoricoxib
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Bnai Zion Medical Center
Colorectal Neoplasm, Hereditary Nonpolyposis
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
This is a randomized, placebo-controlled Phase I/II multi-center trial, of the safety and efficacy of Celecoxib in a cohort of 81 HNPCC subjects and gene carriers.
- Trial name
- NCT00001693
- Testing
- Celecoxib (SC-58635)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Cancer
A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers
Expression of COX-II has been identified in many types of human cancers. Uterine cancer is the most common gynecologic cancer in the US and there has been an increase in uterine cancer deaths over the past decade mainly due to…
- Trial name
- NCT00231829
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mark H. Einstein
Pain
Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery
This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated with ambulatory arthroscopic…
- Trial name
- NCT00333567
- Testing
- Lumiracoxib
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- Novartis
Preeclampsia
Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia
Preeclampsia is a hypertensive disorder of pregnancy and a leading cause of fetal and maternal morbidity and mortality. Recent findings indicate preeclampsia is an inflammatory disorder associated with increased expression of…
- Trial name
- NCT00442676
- Testing
- Celecoxib
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Electrophysiologic Property of Brain
Impact of Celecoxib on Electrophysiological Property in Brain of Healthy Volunteer
the purposes of this study are to evaluate the acute electrophysiological response in brain cortex to single oral dose of celecoxib (400mg once) in healthy volunteer and the electrophysiological alteration in brain cortex by…
- Trial name
- NCT02711579
- Testing
- Celecoxib
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Musculoskeletal Pain
Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
This study is designed to develop our understanding of the risk-benefit of using lumiracoxib in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury.
- Trial name
- NCT00170898
- Testing
- Lumiracoxib
- Where
- United Kingdom
- Volunteers
- 419 people
- Sponsor
- Novartis
Colorectal Cancer, Microsatellite Instability High
Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
The PICC-3 study is a multicentre, single-arm, phase II trial evaluating toripalimab plus celecoxib in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer.
- Conditions
- Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency
- Trial name
- PICC-3 (NCT06903858)
- Testing
- Toripalimab plus celecoxib, Non-operative management, Curative-intent surgery
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Causalgia
Efficacy of Parecoxib on Patients With CRPS
The complex regional pain syndrom is a weighty disease that often results in a lifelong disability. Mostly this disease appears unilateral after comparatively mundane fractures or operations.
- Trial name
- NCT01523379
- Testing
- Parecoxib
- Sponsor
- Ruhr University of Bochum
Breast Cancer
Protocol for Women at Increased Risk of Developing Breast Cancer
To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.
- Trial name
- NCT00291694
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Causalgia, Polyneuropathy
Efficacy of Etoricoxib on Peripheral Hyperalgesia
The purpose of the study is to determine the efficacy of etoricoxib on pain patients. The investigators assume that patients with neuropathic pain will have greater pain relief then patients on placebo.
- Conditions
- Causalgia, Polyneuropathy, Postherpetic Neuralgia, Peripheral Nerve Injury
- Trial name
- NCT01088256
- Testing
- Etoricoxib
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- Ruhr University of Bochum